¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mammary derived growth inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® growth hormone ÇÑ±Û ¼ºÀåÈ£¸£¸ó
¼³¸í   
  ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼­ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀڱصǸ砼Ҹ¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼­ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŰ¸ç Æ¯È÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇϴ °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼­ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇ̵Ǹ頼ºÀåºÎÁøÀÌ ¿Â´Ù.
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® mammary papilla, nipple ÇÑ±Û À¯µÎ, Á¥²ÀÁö
¼³¸í   
  Á¥»ù¿¡¼­ ¸¸µé¾îÁø ¸ðÀ¯°¡ ³ª¿À´Â Åë·Î¿¡ ÇØ´ç.
¿µ¹® mammary glands ÇÑ±Û Á¥»ù, À¯¼±
¼³¸í   
  Á¤»óÀûÀ¸·Î ¾Æ±â¸¦ ³ºÀº »ê¸ð¿¡¼­´Â ³ú¿¡¼­ Á¥ºÐºñÈ£¸£¸ó(prolactin)ÀÇ ºÐºñ°¡ Áõ°¡ÇÏ¿© Á¥»ù¿¡¼­ Á¥À» ¸¸µé°Ô µÈ´Ù. ÀÌ ¶§ Á¥ÀÇ ºÐºñ¸¦ ÃËÁø½Ã۴ °ÍÀ¸·Î´Â ¾Æ±â°¡ Á¥À» ºü´Â ÇàÀ§ µîÀÌ ÀÖÀ¸¸ç, Á¥»ù¿¡¼­ »ý»êµÈ ¸ðÀ¯´Â Á¥»ù°üÀ» °ÅÃÄ Á¥²ÀÁö¸¦ ÅëÇØ ¹ÛÀ¸·Î ³ª°¡°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ, ´ë½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • derived protein
    À¯µµ´Ü¹éÁú
  • endothelium-derived contracting factor
    ³»ÇÇÀ¯·¡¼öÃàÀÎÀÚ
  • endothelium-derived relaxing factor
    ³»ÇÇÀ¯·¡ÀÌ¿ÏÀÎÀÚ
  • membrane-derived oligosaccharide
    ¼¼Æ÷¸·À¯·¡¼Ò´ç·ù, ¼¼Æ÷¸·À¯·¡¿Ã¸®°í´ç·ù
  • internal mammary artery
    ¼Ó°¡½¿µ¿¸Æ, ³»È䵿¸Æ
  • mammary
    À¯¹æ-, Á¥-
  • mammary areola
    Á¥²ÉÆÇ, À¯·û
  • mammary duct ectasia
    Á¥»ù°üÈ®Àå(Áõ), À¯¼±°üÈ®Àå(Áõ)
  • mammary dysplasia
    À¯¹æÇü¼ºÀÌ»ó
  • mammary fold
    Á¥»ùÁÖ¸§
  • mammary gland
    Á¥»ù, À¯¼±
  • mammary papilla
    Á¥²ÀÁö, À¯µÎ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • mammary gland
    Á¥»ù
  • mammary
    À¯¹æ-
  • inhibitor
    ¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
  • growth factor
    ¼ºÀåÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • peak growth velocity
    Ãִ뼺Àå¼Óµµ
  • growth zone
    ¼ºÀ屸¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • thymus-derived cell
    °¡½¿»ùÀ¯·¡¼¼Æ÷
  • derived protein
    À¯µµ´Ü¹éÁú
  • endothelium-derived contracting factor
    ³»ÇǼ¼Æ÷¼öÃàÀÎÀÚ
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷ÀÌ¿ÏÀÎÀÚ
  • thymus-derived lymphocyte
    °¡½¿»ùÀ¯·¡¸²ÇÁ±¸
  • membrane-derived oligosaccharide
    ¼¼Æ÷¸·À¯·¡¼Ò´ç·ù
  • internal mammary artery
    (¢¡internal thoracic artery) ¼Ó°¡½¿µ¿¸Æ
  • mammary areola
    Á¥²ÉÆÇ
  • mammary dysplasia
    À¯¹æÇü¼ºÀÌ»ó
  • mammary duct ectasia
    Á¥»ù°üÈ®Àå(Áõ)
  • mammary fold
    Á¥»ùÁÖ¸§
  • mammary gland
    Á¥»ù
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • growth arrest line (=growth recovery line)
    ¼ºÀå Áö¿¬¼±
  • Caesarian derived =caesarian-originated
    Á¦(¿Õ)Àý(°³)À¯·¡(ð¨èÝôîËÒ ë¦ÕÎ)ÀÇ.
  • EDCF (endothlium-derived contracting factor)
    ³»ÇǼ¼Æ÷¼º(Ò®ù«á¬øààõ) ¼öÃàÀÎÀÚ(â¥õêì×í­)
  • EDRF (endothlium-derived relaxing factor)
    ³»ÇǼ¼Æ÷¼º(Ò®ù«á¬øààõ) ÀÌ¿ÏÀÎÀÚ(ì¬èÐì×í­)
  • EDRF=£¾endothelium derived relaxing factor
    ³»ÇǼ¼Æ÷¼ºÀÌ¿ÏÀÎÀÚ.
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • CAI=£¾carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à, ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú.
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò ¾ïÁ¦Á¦.
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • macrophage,macrophage derived growth factor
    ´ë½Ä¼¼Æ÷±â¿ø ¼ºÀåÀÎÀÚ(¡­ÑÃê¹ à÷íþì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • growth arrest line (=growth recovery line)
    ¼ºÀå Áö¿¬¼±
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • cell, thymus-derived
    °¡½¿»ùÀ¯·¡¼¼Æ÷, Èä¼±À¯·¡¼¼Æ÷
  • derived protein
    À¯µµ´Ü¹éÁú(¡­Ó±ÛÜòõ).
  • endothelium-derived contracting factor (EDCF)
    ³»ÇǼ¼Æ÷¼º¼öÃàÀÎÀÚ(Ò®ù«á¬øààõâ¥õêì×í­)
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ.
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ(¡­ì¬èÐì×í­).
  • endothelium-derived relaxing factor
    ³»ÇÇ ¼¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ
  • endothelium-derived relaxing factor (EDRF)
    ³»ÇǼ¼Æ÷¼ºÀÌ¿ÏÀÎÀÚ
  • eosinophil-derived neurotoxin
    È£»ê±¸À¯·¡½Å°æµ¶¼Ò
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Appositional growth
    µ¡ºÙÀ̼ºÀå
    [¿¾ ¿ë¾î] ÷°¡¼ºÀå
  • Abnormal growth
    ºñÁ¤»ó¼ºÀå
    [¿¾ ¿ë¾î] ºñÁ¤»ó¼ºÀå
  • Interstitial growth
    »çÀÌÁú¼ºÀå
    [¿¾ ¿ë¾î] °£Áú¼ºÀå
  • Growth abnormality
    ¼ºÀåÀÌ»ó
    [¿¾ ¿ë¾î] ¼ºÀåÀÌ»ó
  • Growth defect
    ¼ºÀå°áÇÔ
    [¿¾ ¿ë¾î] ¼ºÀå°áÇÔ
  • Growth cone
    ¼ºÀå¿ø»Ô
    [¿¾ ¿ë¾î] ¼ºÀå¿øÃß
  • Lateral mammary branches
    °¡ÂÊÁ¥»ù°¡Áö
    [¿¾ ¿ë¾î] ¿ÜÃøÀ¯¼±Áö
  • Medial mammary branches
    ¾ÈÂÊÁ¥»ù°¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÀ¯¼±Áö
  • Mammary papilla
    Á¥²ÀÁö [À¯µÎ]
    [¿¾ ¿ë¾î] À¯µÎ
  • Mammary line
    Á¥²ÀÁö¼±
    [¿¾ ¿ë¾î] À¯µÎ¼±
  • Mammary ridge
    Á¥´É¼±
    [¿¾ ¿ë¾î] À¯¸ª
  • Mammary ridge
    Á¥´É¼±
    [¿¾ ¿ë¾î] À¯¹æ¸ª
  • Mammary region
    Á¥ºÎÀ§
    [¿¾ ¿ë¾î] À¯¹æºÎ
  • Mammary gland
    Á¥»ù
    [¿¾ ¿ë¾î] À¯¼±
  • Lobules of mammary gland
    Á¥»ù¼Ò¿±
    [¿¾ ¿ë¾î] À¯¼±¼Ò¿±
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • derived carbohydrate
    À¯µµ´çÁú(ë¯ÓôÓØòõ)
  • derived lipid
    À¯µµÁöÁú(ë¯Óôò·òõ)
  • derived protein
    À¯µµ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • primary derived protein
    ÀÏÂ÷ À¯µµ ´Ü¹éÁú(ìéó­ë¯ÓôÓ±ÛÜòõ)
  • secondary derived protein
    ÀÌÂ÷ À¯µµ´Ü¹éÁú(ì£ó­ë¯ÓôÓ±ÛÜòõ)
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • Bowman-Birk inhibitor
    "º¸¿ì¸¸-¹÷Å© ÀúÇØÀÚ(îÁúªí­), º¸¿ì¸¸-¹÷Å© ÀúÇØÁ¦(îÁúªð¥)"
  • competitive inhibitor
    °æÇÕÀúÇØÁ¦(ÌæùêîÁúªð¥)
  • enzyme-inhibitor complex
    È¿¼Ò-ÀúÇØÁ¦ º¹ÇÕü (ý£áÈîÁúªð¥ÜÜùêô÷)
  • heme-controlled inhibitor
    Èû-Á¦¾î(ð¤åÙ) ÀúÇØÁ¦(îÁúªð¥)
  • inhibitor
    ÀúÇØÁ¦(îÁúªð¥)
  • inhibitor constant
    ÀúÇØÁ¦»ó¼ö(îÁúªð¥ßÈâ¦)
  • irreversible inhibitor
    ºñ°¡¿ª ÀúÇØÁ¦(ުʦæ½îÁúªð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦Á¦, ¾ïÁ¦¹°Áú, ¾ïÁ¦ÀÎÀÚ, ¾ïÁ¦½Å°æ, ¾ïÁ¦À¯ÀüÀÚ, ¾ïÁ¦¾à
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • internal mammary artery
    ³»À¯µ¿¸Æ
  • mammary
    À¯¹æÀÇ
  • mammary abscess
    À¯¹æ³ó¾ç
  • mammary cancer
    À¯¾Ï
  • mammary gland
    Á¥»ù, À¯¼±
  • growth
    ¼ºÀå
  • growth abnormality
    ¹ßÀ°ÀÌ»ó
  • growth and development
    ¼ºÀå°ú ¹ßÀ°
  • growth arrest line
    ¼ºÀåÁö¿¬¼±
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth line
    ¼ºÀå¼±
  • growth retardation
    ¼ºÀåÁö¿¬
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MTV mammary tumor virus; metatarsus varus; mouse mammary tumor virus
BPTI basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in...
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
NG nasogastric; neoplastic growth; new growth; nitroglycerin; nodose ganglion; no growth; not given
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MDGI Mammary derived growth inhibitor
PDGF Anti-platelet-derived growth factor
EDGF Eye Derived Growth Factor
PDGF Plateled derived growth factor
PDGF BB Platelet Derived Growth Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • axillary mammary papilla
    °Üµå¶û À¯µÎ
  • internal mammary artery
    ³»À¯¹æ µ¿¸Æ
  • mammary
    À¯¹æÀÇ, °¡½¿ÀÇ
    À¯¹æ, ȤÀº °¡½¿¿¡ °ü°èµÇ´Â.
  • mammary cancer
    À¯¾Ï
    Á¥»ù¿¡¼­ ¹ß»ýÇÏ´Â À¯¹æÀÇ ¾Ï. Àڱ⠰˻ç¹ýÀ¸·Î Á¶±â ¹ß°ßÀÌ °¡´ÉÇÏ´Ù. ³²¼ºÀÇ À¯¹æ ¾ÏÀº ¿©¼ºÀÇ ¾à 1/100·Î ¸Å¿ì µå¹°´Ù. ¹éÀÎ, ƯÈ÷ ºÏÀ¯·´°èÀÇ ¿©¼º¿¡°Ô ¸¹Àºµ¥, ÇÏ¿ÍÀÌ °ÅÁÖÀÚÀÇ Á¶»ç
  • mammary gland
    Á¥»ù, À¯¼±
    Æ÷À¯·ùÀÇ À¯¹æ ¼Ó¿¡ ÀÖÀ¸¸ç Á¥À» ºÐºñÇÏ´Â ¼±. ÇǺμ±ÀÇ ÀÏÁ¾À¸·Î, ¶¡»ù¿¡¼­ ÁøÈ­ÇÑ °ÍÀÌ´Ù. ÀÚ¿õ ¸ðµÎ¿¡ ÀÖÁö¸¸ ¿õ¼ºÀÇ Å¾ƴ ¹ß»ýÀÇ Ãʱ⠴ܰ迡 ±× Á¤¼Ò¿¡¼­ ºÐºñµÇ´Â ¿õ¼º È£¸£¸ó¿¡ ÀÇÇØ ±× ¹ß´ÞÀÌ ÀúÁöµÇ¾î ÅðÈ­ÇÑ´Ù. ¸¹Àº Æ÷À¯·ùÀÇ Á¥»ùÀº ¸¶Ä¡ ³ª¹µ°¡Áö ¸ð¾çÀ¸·Î À¯°üÀÌ ºÐÁöÇØ ÀÖÀ¸¸ç, ±× »Ñ¸®°¡ À¯µÎ¶ó´Â À¶±â À§¿¡ °³±¸Çϰí ÀÖ´Ù. ÃÖÇϵîÀÇ Æ÷À¯·ùÀÎ ´Ü°ø·ùÀÇ ¿À¸®³Ê±¸¸®ÀÇ Á¥»ùÀº ¸öÀÇ Á¿쿡 1½ÖÀÌ ÀÖ°í À¯µÎ´Â ¾ø´Âµ¥, Á¥À» ¸ÔÀÏ ¶§ ¾î¹Ì´Â À§¸¦ º¸°í ´¯°í »õ³¢´Â ´Ü¼øÇÑ ±¸¸Û¿¡¼­ ½º¸ç³ª¿À´Â Á¥À» ÇӴ´Ù. °°Àº ´Ü°ø·ù¿¡ ¼ÓÇÏ´Â ´Ù¸¥ µ¿¹°ÀÇ Á¥»ùÀº ¾à°£ ¿À¸ñÇÑ À¯³¶ ¼Ó¿¡ ÀÖ´Ù. À̺¸´Ù ´õ ¹ß´ÞÇÑ °ÍÀÌ À¯´ë·ùÀÇ À°¾Æ³¶ÀÌ´Ù. À¯°üÀº ÀÚ¼º È£¸£¸ó, ¼ºÀå È£¸£¸ó, ºÎ½Å ÇÇÁú È£¸£¸ó µî¿¡ ÀÇÇØ ¹ß´ÞÇϴµ¥, À¯ÁóÀ» »ý»êÇÏ´Â ¸»´ÜºÎÀÇ ¹ß´Þ¿¡´Â À¯¼± Àڱؼº È£¸£¸óÀÌ ÇÊ¿äÇÏ´Ù. ÀÓ½ÅÇÏ¸é ¿©¼º È£¸£¸óÀÌ ´Ù·®À¸·Î ºÐºñµÇ¾î Á¥»ùÀÌ ¶Ñ·ÇÇÏ°Ô ¹ß´ÞÇϰí, ºÐ¸¸ Á÷ÈÄ¿¡´Â À¯¼± ÀÚ±Ø È£¸£¸óÀÌ Áõ°¡ÇÏ¿© ±× ÀÛ¿ëÀ¸·Î À¯ÁóÀÇ ºÐºñ°¡ ÀϾ´Ù. À¯ÁóÀÇ »çÃâÀº À¯¾Æ¿¡ ÀÇÇÑ À¯µÎ ÈíÀÎ ÀÚ±ØÀÌ ÁßÃß¿¡ Àü´ÞµÇ°í, ³úÇϼöü ÇÏ¿± È£¸£¸óÀÎ ¿Á½ÃÅä½ÅÀÌ ºÐºñµÇ¾î À̰ÍÀÌ À¯·ûÀÇ ±ÙÀ°À» ¼öÃà½ÃÄѼ­ ÀϾ´Ù.
  • bone marrow-derived lymphocyte
    °ñ¼ö À¯·¡ Àӯı¸
  • bursa-derived lymphocyte
    ÆÄºÎ¸®½Ã¿ì½º ³¶ À¯·¡ Àӯı¸
  • endothelium-derived relaxing factor
    ³»ÇÇ ¼¼Æ÷¼º ÀÌ¿Ï ÀÎÀÚ
  • eosinophil-derived neurotoxin
    È£»ê±¸ À¯·¡ ½Å°æ µ¶¼Ò
  • prodynorphin-derived fragment
    ÇÁ·Î´ÙÀ̳븣ÇÉ À¯·¡ ºÐÀý
  • proenkephalin-derived peptide
    ÇÁ·Î¿£ÄÉÆÈ¸° À¯·¡ ÆéƼµå
  • psychomerically derived test
    ½É¸® ÃøÁ¤ °Ë»ç
  • thymus-derived lymphocyte
    Èä¼± À¯·¡ Àӯı¸
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ ÀÀ°í °áÇÕü
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
mammary derived growth inhibitor Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
brain-derived growth factor <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3.
In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF.
In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons.
Acronym: BDGF
(12 Dec 1998)
receptors, platelet-derived growth factor Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain.
(12 Dec 1998)
platelet-derived growth factor <growth factor> The major mitogen in serum for growth in culture of cells of connective tissue origin. It consists of 2 different but homologous polypeptides A and B (~30,000 D) linked by disulphide bonds. Believed to play a role in wound healing.
It is carried in the alpha-granules of platelets and is released when platelets adhere to traumatised tissues. Connective tissue cells near the traumatised region respond by initiating the process of replication.
The B chain is almost identical in sequence to p28sis, the transforming protein of simian sarcoma virus, that can transform only those cells that express receptors for platelet derived growth factor, suggesting that transformation is caused by autocrine stimulation. The receptor is a tyrosine kinase.
Acronym: PDGF
(12 Dec 1998)
schwannoma derived growth factor <growth factor> A growth factor containing an EGF like domain, mitogenic for astrocytes, Schwann cells and fibroblasts.
(18 Nov 1997)
endothelium-derived growth factor synthase <enzyme> Converts l-arginine to a smooth muscle relaxing factor and stimulates the formation of cyclic-GMP
Registry number: EC 1.5.1.-
Synonym: edrf synthase
(26 Jun 1999)
brain-derived neurotrophic factor <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3.
In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF.
In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons.
Acronym: BDGF
(12 Dec 1998)
refuse-derived fuel (RDF) Fuel prepared from municipal solid waste. Noncombustible materials such as rocks, glass, and metals are removed, and the remaining combustible portion of the solid waste is choped or shreaded. RDF facilities process between 100 and 3000 tons of MSW per day.
(05 Dec 1998)
monocyte derived neutrophil chemotactic factor <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
derived protein A derivative of protein effected by chemical change, e.g., hydrolysis.
(05 Mar 2000)
oxygen derived free radicals An atom or atom group having an unpaired electron on an oxygen atom, typically derived from molecular oxygen. For example, one-electron reduction of O2 produces the superoxide radical, O2-; other examples include the hydroperoxyl radical (HOO-), the hydroxyl radical (HO-), and nitric oxide (NO-).
(05 Mar 2000)
thymus derived lymphocyte <haematology, immunology> A class of lymphocytes, so called because they are derived from the thymus and have been through thymic processing. Involved primarily in controlling cell-mediated immune reactions and in the control of B-cell development. The T-cells coordinate the immune system by secreting lymphokine hormones.
There are 3 fundamentally different types of t cells : helper, killer, and suppressor. Each has many subdivisions. T-cells are also called t lymphocytes.
They bear T-cell antigen receptors (CD3) and lack Fc or C3b receptors. Major T-cell subsets are CD4 (mainly helper cells) and CD8 (mostly cytotoxic or suppressor T-cells). Uncontrolled proliferation of this type of cell gives rise to T-cell leukaemia/lymphoma.
(21 Jun 1999)
endothelium derived relaxation factor <biochemistry> This compound is produced from L arginine by the enzyme nitric oxide synthase. Acts as a potent vasorelaxant via elevation of intracellular cGMP in vascular smooth muscle.
Synthesis of nitric oxide is not confined to endothelium, isoforms of nitric oxide synthase are also found in brain, neutrophils and platelets.
Synonym: endothelium derived relaxation factor.
Acronym: NO
(29 Dec 1997)
endothelium-derived relaxing factor A labile humoral agent released by the vascular endothelium that mediates the relaxation induced by some vasodilators such as acetylcholine and bradykinin. Edrf also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. These actions are believed to be mediated through stimulation of guanylate cyclase and the consequent elevation of cyclic guanosine 3',5'-monophosphate. Edrf is thought to be nitric oxide or a ready source of it. The factor is believed to be unstable and acts only locally in vivo.
(12 Dec 1998)
body of mammary gland The principal part of the breast, consisting of glandular tissue and its supporting fibrous tissue. It forms a conical mass converging toward the nipple and is surrounded by adipose tissue.
Synonym: corpus mammae.
(05 Mar 2000)
paget's disease, mammary An intraductal carcinoma of the breast extending to involve the nipple and areola, characterised clinically by eczema-like inflammatory skin changes and histologically by infiltration of the dermis by malignant cells (paget's cells).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • derived
    À¯·¡µÈ;ÆÄ»ýµÈ(´Ü¾î)
  • inhibitor
    ¾ïÁ¦ÀÚ(¹°);¹ÝÀÀ¾ïÁ¦Á¦
  • mammary
    À¯¹æÀÇ;the ~ gland Á¥»ù 9
  • mammary gland
    À¯¼±
  • growth
    ¼ºÀå,¹ß´Þ,Áõ°¡
  • economic growth rate
    °æÁ¦ ¼ºÀå·ü 9
  • growth
    ¼ºÀå;»ýÀå;¹ßÀ°;¹ß´Þ;Áõ´ë;Àç¹è;»ýÀå(¹ß»ý)¹°;»ê¹°
  • growth center
    (sensitivity trainingµîÀ»ÇÏ´Â)´É·Â °³¹ß ¼¾ÅÍ)
  • growth hormone
    ¼ºÀå È£¸£¸ó 
  • growth industry
    ¼ºÀå »ê¾÷
  • growth stock
    ¼ºÀåÁÖ
  • human growth hormone
    Àΰ£¼ºÀå È£¸£¸ó(ÀÎüÀÇ ¼ºÀåÀ» Áö¹èÇÏ´Â ³úÇϼöü Á¾ÇÕ È£¸£¸ó)
  • mushroom growth
    ±Þ°ÝÇÑ ¼ºÀå
  • negative growth
    (°æÁ¦ÀÇ)¸¶À̳ʽº ¼ºÀå
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á